Vera Therapeutics, Inc. Class A VERA 深 沪
等待开盘 06-30 09:30:00 美东时间
43.15
+0.690
+1.63%
华盛通- 最 高44.04
- 今 开43.41
- 成交量 339.38万股
- 最 低 41.41
- 昨 收 42.46
- 总市值 30.97亿
- 52周最高 56.05
- 市盈率 静 --
- 换手率 4.73%
- 52周最低 19.0663
- 委 比 -29.59%
- 总股本 7178.29万
- 历史最高 56.05
- 量 比 1.28
- 振 幅 6.19%
- 历史最低 5.20
- 每 手 1
- 风险率 9.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股夜盘 | Viridian Therapeutics, Inc.涨12.29%，温迪-阿比斯饭店涨8.59%
Viridian Therapeutics, Inc.涨12.29%；温迪-阿比斯饭店涨8.59%；Vera Therapeutics, Inc. Class A涨7.68%
06-29 09:00
美股夜盘 | Synaptics Incorporated涨6.64%，Vera Therapeutics, Inc. Class A涨4.49%
Synaptics Incorporated涨6.64%；Vera Therapeutics, Inc. Class A涨4.49%；Tango Therapeutics, Inc.涨3.05%
06-26 15:01
美股夜盘 | Synaptics Incorporated涨7.37%，Vera Therapeutics, Inc. Class A涨4.07%
Synaptics Incorporated涨7.37%；Vera Therapeutics, Inc. Class A涨4.07%；Tango Therapeutics, Inc.涨3.05%
06-26 13:01
美股夜盘 | Synaptics Incorporated涨8.71%，Vera Therapeutics, Inc. Class A涨4.25%
Synaptics Incorporated涨8.71%；Vera Therapeutics, Inc. Class A涨4.25%；Equinox Gold Corp.涨3.83%
06-26 10:01
美股夜盘 | Synaptics Incorporated涨9.46%，Vera Therapeutics, Inc. Class A涨4.69%
Synaptics Incorporated涨9.46%；Vera Therapeutics, Inc. Class A涨4.69%；Equinox Gold Corp.涨3.83%
06-26 09:01
Vera Therapeutics股价涨3.15%，核心药物监管进展成驱动
经济观察网 Vera Therapeutics, Inc.核心药物阿他西普监管路径明确，带动股价上涨，后续试验数据公布将影响其后续发展。 股票近期走势： Ve...
06-12 23:04
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics granted inducement awards, including stock options and RSUs, to 10 new employees under the 2024 Inducement Plan on June 2, 2026. The stock options, totaling 28,800 shares, and RSUs, totaling 14,150 shares, have an exercise price of $31.26 per share, based on Vera's closing price on June 2, 2026. Both options and RSUs vest over four years, with options vesting monthly after the first anniversary and RSUs vesting annually on speci...
06-05 20:05
Vera Moves Up Key FDA Review Timeline for Kidney Disease Drug, Expects Critical Trial Results in Third Quarter of 2026
Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced it has aligned with the
06-02 19:15
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
Vera Therapeutics announced alignment with the FDA on an earlier ORIGIN 3 eGFR analysis for atacicept in IgAN, now expected in Q3 2026. The company plans to submit an sBLA for full approval in Q4 2026, with potential approval in 2027. Atacicept, targeting BAFF and APRIL, has shown significant proteinuria reduction and eGFR stabilization in Phase 2b and 3 trials. The revised timeline aims to accelerate full approval for this potential first-in-cla...
06-02 11:00
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
